Oncolytics Biotech Inc. (ONCY) Research

Oncolytics Biotech Inc. is a biopharmaceutical firm in its development phase, concentrating its efforts on discovering and creating novel pharmaceutical agents to combat cancer. Its primary therapeutic candidate is pelareorep, an immunotherapeutic drug delivered intravenously, designed to target and treat both solid tumors and various blood-related cancers. The company has established strategic co-development agreements with major pharmaceutical companies, Merck KGaA and Pfizer Inc., as well as with PrECOG LLC. These collaborations are focused on advancing pelareorep for use in conjunction with paclitaxel and avelumab (a human anti-PD-L1 antibody). This specific combination therapy is being developed to address hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer. Oncolytics Biotech Inc. was founded in 1998 and is based in Calgary, Canada.

Market snapshot

Symbol
ONCY
Price
$0.96
Day change
+3.03%
Market cap
$136.2M
P/E ratio
-4.29x
52-week range
0.56-1.51
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Recent news

  • Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks

    Oncolytics Biotech, Inc. (NASDAQ:ONCY) shares are up on Monday as the company reported promising durability data for its investigational immunotherapy, pelareorep, in treating metastatic colorectal cancer.

Peer companies

  • Atossa Therapeutics, Inc. (ATOS)
  • Clene Inc. (CLNN)
  • Coya Therapeutics, Inc. (COYA)
  • Immix Biopharma, Inc. (IMMX)
  • MacroGenics, Inc. (MGNX)
  • Surrozen, Inc. (SRZN)
  • Instil Bio, Inc. (TIL)
  • Tevogen Bio Holdings Inc. (TVGN)

Recent insider activity

  • McAdory John Bearden — trade (500000 shares) on 2026-06-01
  • Glover Stephen C. — trade (0 shares) on 2026-06-01
  • Parsons James T. — P-Purchase (10000 shares) on 2026-03-11
  • Kelly Jared — P-Purchase (5050 shares) on 2026-03-12
  • Kelly Jared — P-Purchase (29500 shares) on 2026-02-12

Open Oncolytics Biotech Inc. (ONCY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.